KR20260062967A - 사이클릭 포스페이트 화합물 - Google Patents
사이클릭 포스페이트 화합물Info
- Publication number
- KR20260062967A KR20260062967A KR1020267009794A KR20267009794A KR20260062967A KR 20260062967 A KR20260062967 A KR 20260062967A KR 1020267009794 A KR1020267009794 A KR 1020267009794A KR 20267009794 A KR20267009794 A KR 20267009794A KR 20260062967 A KR20260062967 A KR 20260062967A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- alkyl
- alkoxy
- halo
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837137P | 2019-04-22 | 2019-04-22 | |
| US62/837,137 | 2019-04-22 | ||
| KR1020217037884A KR20210154229A (ko) | 2019-04-22 | 2020-04-21 | 사이클릭 포스페이트 화합물 |
| PCT/US2020/029149 WO2020219464A1 (en) | 2019-04-22 | 2020-04-21 | Cyclic phosphate compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037884A Division KR20210154229A (ko) | 2019-04-22 | 2020-04-21 | 사이클릭 포스페이트 화합물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260062967A true KR20260062967A (ko) | 2026-05-07 |
Family
ID=72941350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267009794A Pending KR20260062967A (ko) | 2019-04-22 | 2020-04-21 | 사이클릭 포스페이트 화합물 |
| KR1020217037884A Ceased KR20210154229A (ko) | 2019-04-22 | 2020-04-21 | 사이클릭 포스페이트 화합물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037884A Ceased KR20210154229A (ko) | 2019-04-22 | 2020-04-21 | 사이클릭 포스페이트 화합물 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220220145A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3966221A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7661235B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260062967A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113939526A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020263283B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3136954A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX428883B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020219464A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019207626B2 (en) | 2018-01-10 | 2023-10-05 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| MX428883B (es) * | 2019-04-22 | 2025-11-13 | Ligand Pharm Inc | Compuestos ciclicos de fosfato |
| WO2021011692A1 (en) | 2019-07-17 | 2021-01-21 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| EP4143199B1 (en) * | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| WO2021216431A1 (en) * | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Benzyloxy phosph(on)ate compounds |
| JP7699205B2 (ja) * | 2020-10-21 | 2025-06-26 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 抗ウイルスプロドラッグ化合物 |
| US20240294565A1 (en) * | 2021-05-17 | 2024-09-05 | Ligand Pharmaceuticals Incorporated | Unnatural configuration nucleotide prodrug compounds |
| CN118005694B (zh) * | 2023-01-06 | 2025-04-22 | 北京双鹤润创科技有限公司 | 一种环状核苷类似物及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6023120B2 (ja) * | 1979-08-13 | 1985-06-05 | キッコーマン株式会社 | アデノシン−3′,5′−環状リン酸アルキルトリエステルの製造法 |
| DE3027279A1 (de) * | 1980-07-18 | 1982-05-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5866548A (en) * | 1993-04-09 | 1999-02-02 | The Regents Of The University Of California | Caged membrane-permeant inositol phosphates |
| US5693521A (en) * | 1993-04-09 | 1997-12-02 | The Regents Of The University Of California | Membrane-permeant second messengers |
| US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| WO2007027248A2 (en) * | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8772474B2 (en) * | 2010-12-22 | 2014-07-08 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| WO2013177195A1 (en) * | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| ES2674980T3 (es) * | 2012-10-08 | 2018-07-05 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloro nucleósidos para infección por VHC |
| JP2016501200A (ja) * | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体 |
| US9243022B2 (en) * | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3131914B1 (en) * | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| EP3471737B1 (en) * | 2016-06-20 | 2025-06-04 | Merck Sharp & Dohme LLC | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| CN111491634A (zh) | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | 有机磷酸酯衍生物 |
| CN111801339B (zh) | 2018-01-19 | 2025-06-24 | 纽科利制药公司 | 5-氟尿嘧啶化合物 |
| AU2019227986A1 (en) * | 2018-03-02 | 2020-10-08 | January Therapeutics, Inc. | Nanoparticle compositions |
| MX428883B (es) * | 2019-04-22 | 2025-11-13 | Ligand Pharm Inc | Compuestos ciclicos de fosfato |
-
2020
- 2020-04-21 MX MX2021012894A patent/MX428883B/es unknown
- 2020-04-21 AU AU2020263283A patent/AU2020263283B2/en active Active
- 2020-04-21 JP JP2021559729A patent/JP7661235B2/ja active Active
- 2020-04-21 KR KR1020267009794A patent/KR20260062967A/ko active Pending
- 2020-04-21 CA CA3136954A patent/CA3136954A1/en active Pending
- 2020-04-21 US US17/604,681 patent/US20220220145A1/en active Pending
- 2020-04-21 EP EP20796308.3A patent/EP3966221A4/en active Pending
- 2020-04-21 WO PCT/US2020/029149 patent/WO2020219464A1/en not_active Ceased
- 2020-04-21 KR KR1020217037884A patent/KR20210154229A/ko not_active Ceased
- 2020-04-21 CN CN202080038544.0A patent/CN113939526A/zh active Pending
-
2025
- 2025-04-02 JP JP2025060882A patent/JP2025106352A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3136954A1 (en) | 2020-10-29 |
| JP2025106352A (ja) | 2025-07-15 |
| MX2021012894A (es) | 2021-11-17 |
| EP3966221A1 (en) | 2022-03-16 |
| JP7661235B2 (ja) | 2025-04-14 |
| WO2020219464A1 (en) | 2020-10-29 |
| JP2022529321A (ja) | 2022-06-21 |
| CN113939526A (zh) | 2022-01-14 |
| KR20210154229A (ko) | 2021-12-20 |
| AU2020263283B2 (en) | 2026-04-23 |
| MX428883B (es) | 2025-11-13 |
| US20220220145A1 (en) | 2022-07-14 |
| AU2020263283A1 (en) | 2021-12-16 |
| EP3966221A4 (en) | 2023-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7661235B2 (ja) | 環状リン酸エステル化合物 | |
| TWI838355B (zh) | 5-氟尿嘧啶化合物 | |
| US10435429B2 (en) | 5-fluorouridine monophosphate cyclic triester compounds | |
| KR102708995B1 (ko) | 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물 | |
| CN115605492B (zh) | 核苷酸前药化合物 | |
| EA024804B1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение | |
| WO2022245584A1 (en) | Unnatural configuration nucleotide prodrug compounds | |
| TWI864050B (zh) | 環狀去氧核糖核苷酸化合物 | |
| CN115768778A (zh) | 苄氧基磷酸(膦酸)酯化合物 | |
| RU2836016C2 (ru) | Циклические дезоксирибонуклеотидные соединения | |
| RU2796403C2 (ru) | Фосфор(n)амидатацетальные и фосф(он)атацетальные соединения | |
| WO2023081105A1 (en) | Cyclic phosphoramidate compounds | |
| HK40108726A (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| HK40063264A (en) | Cyclic deoxyribonucleotide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |